Project Grant R03DE033304

Award Date 9/1/24
Completion Date 8/31/26
Dollars Obligated $314K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Ithaca, NY 14853, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $265,650 to support research on the evolutionary dynamics of the opportunistic fungal pathogen Candida glabrata in the gastrointestinal tract. The study aims to elucidate how antifungal drug treatment and immune dysfunction influence the adaptation and evolution of gut-colonizing C. glabrata, which can lead to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 in funding to Hackensack University Medical Center (HUMC) to conduct research on how the fungal pathogen Candida albicans adapts and causes infections in different parts of the human body. The key objectives are to identify and characterize how the C. albicans GCN5 protein, which regulates gene...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the discovery and development of new antifungal therapeutics. The goal is to identify inhibitors of the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth across different environmental conditions. By targeting CER1, the project aims to develop a more potent antifungal...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance the development of natural phenolic compounds, specifically caffeic acid phenethyl ester (CAPE) and ellagic acid (EA), for the management of oral candidiasis. The $416,396 award, running from August 2024 to July 2029, will fund three key objectives: 1) optimizing hydrogels loaded with EA and/or CAPE to...
C. ALBICANS-INTRINSIC MECHANISMS DEFINING GUT COLONIZATION - PROJECT SUMMARY: THE FUNGUS CANDIDA ALBICANS IS A FREQUENT COMMENSAL OF THE GASTROINTESTINAL (GI) TRACT BUT IS ALSO AN IMPORTANT CAUSE OF BOTH MUCOSAL AND SYSTEMIC DISEASE. THE GI POPULATION IS PARTICULARLY RELEVANT TO HUMAN HEALTH AS CELLS CAN TRANSLOCATE OUT OF THIS NICHE TO CAUSE DISSEMINATED INFECTIONS. C. ALBICANS CELLS IN THE GUT ALSO PLAY KEY ROLES IN REGULATING LOCAL AND SYSTEMIC IMMUNE RESPONSES THAT CAN BE EITHER BENEFICIAL...
This $443,944.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by the University of Georgia Research Foundation to study the genetic basis of two key pathogenesis traits in the fungal genus Cryptococcus - thermotolerance and azole drug resistance. The research aims to employ high-throughput genetic approaches to characterize how genome-wide factors...
This $134,800 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research will support research to study the role of multi-drug resistant Candida auris Hyr1/Iff-like proteins in virulence and their potential as vaccine targets. The principal investigator, Dr. Shakti Singh, an accomplished immunologist at The Lundquist Institute, will leverage his expertise to fill gaps in his fungal research knowledge...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $642,775 to support research at the University of California, Davis (UC Davis) aimed at accelerating the discovery of novel antifungal peptides. The research will leverage the university's one-bead one-compound (OBOC) combinatorial technology and screening platforms to rapidly identify and optimize membrane-active...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $3,132,562 Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to the University of Massachusetts Lowell to develop and evaluate salivary peptide/protein-based multilayer coatings for controlling Candida biofilm formation and preventing Candida-associated denture stomatitis. The project aims to fabricate rat dentures with the salivary anticandidal coatings, assess their antifungal activity and...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...

DEVELOPMENT OF ANTIFUNGAL DRUG RESISTANCE IN THE ORAL ENVIRONMENT OVER THE COURSE OF HIV INFECTION - FUNGAL INFECTIONS ARE AN INCREASING HUMAN HEALTH RISK, AND THE DEVELOPMENT OF FUNGAL RESISTANCE TO THE LIMITED REPERTOIRE OF AVAILABLE DRUGS IS EXACERBATING THIS THREAT. FIVE SPECIES WITHIN THE GENUS CANDIDA PREDOMINANTLY CAUSE DISEASE MANIFESTATIONS IN HUMANS, ESPECIALLY IN IMMUNOCOMPROMISED INDIVIDUALS. INDEED, CANDIDIASIS IS THE MOST COMMON OPPORTUNISTIC ORAL INFECTION AFFECTING PEOPLE WITH AIDS. EARLIER WORK BY OUR GROUP AND OTHERS DEMONSTRATED CHANGES IN ORAL FUNGAL COMPOSITION AND MUTATIONAL CHANGES IN ANTIMICROBIAL RESISTANCE (AMR) GENES THROUGHOUT THE COURSE OF HIV INFECTION AND TREATMENT, SUGGESTING A UNIQUENESS TO THE ORAL ENVIRONMENT. ALTHOUGH THERE ARE SEVERAL KNOWN MOLECULAR MECHANISMS THAT CONFER ANTIFUNGAL RESISTANCE, RECENT STUDIES SUGGEST THE HIGH LIKELIHOOD THAT THERE ARE MANY NOVEL MECHANISMS YET TO BE IDENTIFIED. OUR GOALS ARE TO EMPLOY EVOLUTIONARY GENOMIC APPROACHES TO GAIN BOTH BASIC AND APPLIED INSIGHTS ON THE ORAL ENVIRONMENT THAT WILL INFORM DIAGNOSTICS AND ULTIMATELY TREATMENT. OUR CENTRAL HYPOTHESIS IS THAT FUNGI WILL EVOLVE OVER TIME IN THE ORAL ENVIRONMENT, AND THIS R03 IS DESIGNED TO DEMONSTRATE BOTH SUPPORT FOR THIS HYPOTHESIS AND FEASIBILITY OF THE NOVEL METHODS WE ARE DEVELOPING. OUR PROPOSED WORK LEVERAGES AN EARLIER CASE-CONTROL STUDY ("CROSSTALK") BY ONE OF OUR TEAM MEMBERS AND INCLUDES A SET OF 50 HIV-POSITIVE AND HAART NAIVE INDIVIDUALS, AND 76 HIV-NEGATIVE CONTROLS, OVER A 5-YEAR STUDY PERIOD. DEIDENTIFIED AND CRYOPRESERVED SALIVA, CARIES SWABS, FUNGAL CULTURES, AND BACTERIAL CULTURES FROM THESE PATIENTS ARE IMMEDIATELY AVAILABLE, ALONG WITH ASSOCIATED CLINICAL AND DEMOGRAPHIC DATA. IN AIM 1 WE WILL USE DIRECT LONG-READ SEQUENCING ON PATIENT SALIVA AND CARIES SWABS TO DETERMINE THE FUNGAL MYCOBIOME AT UNPRECEDENTED RESOLUTION. THIS PROFILING WILL COME FROM DIRECT SEQUENCE ANALYSIS OF THE FULL-LENGTH CANDIDA RRNA OPERON FROM PATIENT SAMPLES. IN AIM 2 WE WILL DETERMINE THE FUNGAL RESISTOME OF THE SAME SAMPLES OVER THE COURSE OF TREATMENT. WE WILL PERFORM LONGITUDINAL PROFILING BY HYBRIDIZATION-CAPTURE WITH BIOTINYLATED PROBES TO TARGET KNOWN FUNGAL AMR AND BIOFILM-ASSOCIATED GENES. THESE GENES WILL THEN BE ANALYZED FOR SNPS OVER TIME AND FOR SIGNATURES OF POSITIVE SELECTION PRESSURE. WE WILL NEXT PROPOSE AN R01 WITH A GOAL OF IDENTIFYING NEW FUNGAL GENETIC AMR DETERMINANTS USING PAN-GENOMIC AND MOLECULAR ADAPTATION ANALYSES ON FUNGAL CULTURES FROM CROSSTALK AND MORE RECENT ISOLATES. THIS TAKES ADVANTAGE OF THE RECENT DISCOVERY THAT FUNGI, LIKE BACTERIA, HAVE A CORE AND AN ACCESSORY GENOME; WE PLAN TO CORRELATE THE GENES FROM THE ACCESSORY GENOME, AND SNPS ACROSS THE GENOME, WITH AMR PHENOTYPE DATA, CONCENTRATING ON CANDIDA SPECIES COMMON TO THE HIV ORAL ENVIRONMENT. WE EXPECT THAT THIS PROJECT WILL IDENTIFY PUTATIVE NOVEL CANDIDA ANTIFUNGAL RESISTANCE MECHANISMS AND PROVIDE MUCH NEEDED INFORMATION ON CANDIDA EVOLUTION IN THE ORAL ENVIRONMENT.

Posted 8/13/24, 12:00 AM